Cargando…

Differences between the efficacy of HER2(2+)/FISH-positive and HER2(3+) in breast cancer during dual-target neoadjuvant therapy

INTRODUCTION: This study investigated the differences in efficacy between IHC(2+)/FISH-positive and IHC(3+) in HER2-positive breast cancer (BC) during neoadjuvant chemotherapy (NAC) combined with trastuzumab and pertuzumab. The research also aimed to provide insight into treatment strategies for cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Wei, Li, Fen-Xiang, Lu, Da-Lin, Jiang, Jun, Li, Junjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400900/
https://www.ncbi.nlm.nih.gov/pubmed/37517155
http://dx.doi.org/10.1016/j.breast.2023.07.008
_version_ 1785084542358388736
author Chen, Wei
Li, Fen-Xiang
Lu, Da-Lin
Jiang, Jun
Li, Junjie
author_facet Chen, Wei
Li, Fen-Xiang
Lu, Da-Lin
Jiang, Jun
Li, Junjie
author_sort Chen, Wei
collection PubMed
description INTRODUCTION: This study investigated the differences in efficacy between IHC(2+)/FISH-positive and IHC(3+) in HER2-positive breast cancer (BC) during neoadjuvant chemotherapy (NAC) combined with trastuzumab and pertuzumab. The research also aimed to provide insight into treatment strategies for clinical HER2(2+)/FISH-positive and HER2(3+) BC. MATERIALS AND METHODS: A retrospective analysis was performed on the clinical and pathological data of patients with confirmed diagnoses of invasive BC treated via combined NAC and dual-target therapy who underwent surgery at the Breast Surgery Center of Sichuan Cancer Hospital between June 2019 and June 2022. The correlation between the clinicopathological characteristics and pathological complete response (pCR) was analyzed via the χ2 test, while logistic regression was performed using the SAS 9.4 statistical analysis software. RESULTS: This study examined 224 patients with an overall pCR rate of approximately 59.82%, which included 36 IHC(2+)/FISH-positive and 188 IHC(3+) cases with approximate pCR rates of 41.67% and 63.30%, respectively. Univariate and multifactorial analysis of the clinical and pathological data determined that age, menstrual status, family history, Ki67 expression, number of treatment cycles, and treatment regimen did not influence pCR. No statistical differences were evident between the univariate and multivariate models. However, the clinical stage, hormone receptor, and HER2 expression status significantly impacted pCR, with considerable consistent differences between the univariate and multifactor analyses. CONCLUSIONS: HER2 IHC(3+) BC displays a higher pCR rate than HER2 IHC(2+)/FISH-positive BC (p ≤ 0.05), with a positive correlation between the HER2 protein expression levels and the response to anti-HER2 therapy.
format Online
Article
Text
id pubmed-10400900
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-104009002023-08-05 Differences between the efficacy of HER2(2+)/FISH-positive and HER2(3+) in breast cancer during dual-target neoadjuvant therapy Chen, Wei Li, Fen-Xiang Lu, Da-Lin Jiang, Jun Li, Junjie Breast Original Article INTRODUCTION: This study investigated the differences in efficacy between IHC(2+)/FISH-positive and IHC(3+) in HER2-positive breast cancer (BC) during neoadjuvant chemotherapy (NAC) combined with trastuzumab and pertuzumab. The research also aimed to provide insight into treatment strategies for clinical HER2(2+)/FISH-positive and HER2(3+) BC. MATERIALS AND METHODS: A retrospective analysis was performed on the clinical and pathological data of patients with confirmed diagnoses of invasive BC treated via combined NAC and dual-target therapy who underwent surgery at the Breast Surgery Center of Sichuan Cancer Hospital between June 2019 and June 2022. The correlation between the clinicopathological characteristics and pathological complete response (pCR) was analyzed via the χ2 test, while logistic regression was performed using the SAS 9.4 statistical analysis software. RESULTS: This study examined 224 patients with an overall pCR rate of approximately 59.82%, which included 36 IHC(2+)/FISH-positive and 188 IHC(3+) cases with approximate pCR rates of 41.67% and 63.30%, respectively. Univariate and multifactorial analysis of the clinical and pathological data determined that age, menstrual status, family history, Ki67 expression, number of treatment cycles, and treatment regimen did not influence pCR. No statistical differences were evident between the univariate and multivariate models. However, the clinical stage, hormone receptor, and HER2 expression status significantly impacted pCR, with considerable consistent differences between the univariate and multifactor analyses. CONCLUSIONS: HER2 IHC(3+) BC displays a higher pCR rate than HER2 IHC(2+)/FISH-positive BC (p ≤ 0.05), with a positive correlation between the HER2 protein expression levels and the response to anti-HER2 therapy. Elsevier 2023-07-24 /pmc/articles/PMC10400900/ /pubmed/37517155 http://dx.doi.org/10.1016/j.breast.2023.07.008 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Chen, Wei
Li, Fen-Xiang
Lu, Da-Lin
Jiang, Jun
Li, Junjie
Differences between the efficacy of HER2(2+)/FISH-positive and HER2(3+) in breast cancer during dual-target neoadjuvant therapy
title Differences between the efficacy of HER2(2+)/FISH-positive and HER2(3+) in breast cancer during dual-target neoadjuvant therapy
title_full Differences between the efficacy of HER2(2+)/FISH-positive and HER2(3+) in breast cancer during dual-target neoadjuvant therapy
title_fullStr Differences between the efficacy of HER2(2+)/FISH-positive and HER2(3+) in breast cancer during dual-target neoadjuvant therapy
title_full_unstemmed Differences between the efficacy of HER2(2+)/FISH-positive and HER2(3+) in breast cancer during dual-target neoadjuvant therapy
title_short Differences between the efficacy of HER2(2+)/FISH-positive and HER2(3+) in breast cancer during dual-target neoadjuvant therapy
title_sort differences between the efficacy of her2(2+)/fish-positive and her2(3+) in breast cancer during dual-target neoadjuvant therapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400900/
https://www.ncbi.nlm.nih.gov/pubmed/37517155
http://dx.doi.org/10.1016/j.breast.2023.07.008
work_keys_str_mv AT chenwei differencesbetweentheefficacyofher22fishpositiveandher23inbreastcancerduringdualtargetneoadjuvanttherapy
AT lifenxiang differencesbetweentheefficacyofher22fishpositiveandher23inbreastcancerduringdualtargetneoadjuvanttherapy
AT ludalin differencesbetweentheefficacyofher22fishpositiveandher23inbreastcancerduringdualtargetneoadjuvanttherapy
AT jiangjun differencesbetweentheefficacyofher22fishpositiveandher23inbreastcancerduringdualtargetneoadjuvanttherapy
AT lijunjie differencesbetweentheefficacyofher22fishpositiveandher23inbreastcancerduringdualtargetneoadjuvanttherapy